Hummingbird Diagnostics to Present New Findings Linking Ribosome Quality Control Pathway to Liquid Biopsy Biomarkers for Lung Cancer at EACR
Hummingbird Diagnostics GmbH, a molecular diagnostics company focused on blood-based tests for early disease detection and precision medicine, today announced that it will present new findings supporting the biological and clinical relevance of its liquid biopsy RNA biomarkers in lung cancer at the upcoming EACR Congress, taking place June 8-11 in Budapest, Hungary.
Hummingbird Diagnostics Publishes Study on RNA Biomarker Methylation in Liquid Biopsies
Hummingbird Diagnostics GmbH, a pioneer in harnessing blood-based small RNAs for early disease detection and characterization, today announced the publication of a new study in Nature Communications Medicine introducing an Oxford Nanopore Technologies (ONT)-based method for detecting small RNA modifications in blood.
Hummingbird Diagnostics Announces Publication Evaluating miR-Blood's Small RNA Expression Dataset Capabilities in Nature’s Scientific Data
Hummingbird Diagnostics GmbH, a leader in using blood-based small RNAs for early disease detection and characterization, today announced a publication in Scientific Data, a peer-reviewed, open-access journal launched by Nature. The study evaluated miR-Blood, Hummingbird Diagnostics’ small RNA expression dataset for eleven major components of human peripheral blood.
Hummingbird Diagnostics Announces Initiation of Patient Recruitment for Clinical Study Evaluating miLungDx as a Novel Diagnostic Test for Early-stage Lung Cancer
Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced the initiation of its clinical study evaluating the diagnostic performance of miLungDx, a blood-based small RNA panel engineered to detect non-small cell lung cancer (NSCLC).
Hummingbird Diagnostics GmbH to Unveil Pioneering Alzheimer's Disease Biomarker Research at CTAD Conference
Hummingbird Diagnostics GmbH, a leader in blood-based small RNA detection and characterization, today announced the presentation of groundbreaking research data at the Clinical Trials in Alzheimer's Disease (CTAD) conference in Boston.
Hummingbird Diagnostics Announces Publication of miLung Small RNA-Based Blood Test for Early Detection of Lung Cancer in the Journal of Thoracic Oncology
Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic Oncology following a poster presentation at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting on the miLung small RNA blood test for early-stage lung cancer detection.
Hummingbird Diagnostics to Present Poster on miLung Small RNA-Based Blood Test at the ASCO 2023 Annual Meeting
Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced a poster presentation at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting on the miLung small RNA blood test for early-stage lung cancer detection.
Hummingbird Diagnostics Publishes Study of miRisk as a Predictor of Immunotherapy Efficacy in Advanced-Stage NSCLC
Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic Oncology Clinical and Research Reports that demonstrates their blood 5-microRNA signature (miRisk) to predict survival following immunotherapy in advanced non-small cell lung cancer (NSCLC) patients with high PD-L1 expression.
Hummingbird Diagnostics Announces Publication of Study on the Utility of miRisk, a Blood-based microRNA Analysis, to Predict Overall Survival for Advanced Non-Small Cell Lung Cancer in npj Precision Oncology
Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced the publication of a study in the journal npj Precision Oncology that describes the discovery and validation of miRisk, a first-of-its-kind microRNA (miRNA) biomarker signature that offers the prospect of a blood-based companion diagnostic for immunotherapy in advanced non-small cell lung cancer (NSCLC). The results of the study illustrate the development of miRisk and its prognostic value for overall survival following immunotherapy. The blood-based test holds the potential for broad applicability for the management of patients with cancer.
